U.S. Markets close in 3 hrs 36 mins

CLASS ACTION UPDATE for UXIN, AVEO, AMRN and AMR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Uxin Limited (UXIN)
Class Period:
Pursuant and/or traceable to the Company’s Registration Statement and Prospectus issued in connection with the June 27, 2018 initial public offering
Lead Plaintiff Deadline: April 12, 2019
Join the action: https://www.zlk.com/pslra-1/uxin-limited-loss-form?wire=3

The Registration Statement was materially false and misleading and omitted to state that: (1) Uxin was likely to stop providing complementary services such as inspections to its customers; (2) instead, Uxin would connect consumers to dealers who would provide such complementary services; (3) as a result, Uxin’s 2B business would be materially impacted; and (4) consequently, Defendants’ statements in the Registration Statement regarding Uxin’s business, operations, and prospects, were materially false and/or misleading.

To learn more about the Uxin Limited class action contact jlevi@levikorsinsky.com.

AVEO Pharmaceuticals, Inc. (AVEO)
Class Period:
August 4, 2016 - January 31, 2019
Lead Plaintiff Deadline: April 26, 2019
Join the action: https://www.zlk.com/pslra-1/aveo-pharmaceuticals-inc-loss-form?wire=3

Allegations: AVEO Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO’s public statements were materially false and misleading at all relevant times.

To learn more about the AVEO Pharmaceuticals, Inc. class action contact jlevi@levikorsinsky.com.

Amarin Corporation (AMRN)
Class Period:
September 24, 2018 - November 9, 2018
Lead Plaintiff Deadline: April 23, 2019
Join the action: https://www.zlk.com/pslra-1/amarin-corporation-loss-form?wire=3

Allegations: During the class period, Amarin Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin's public statements were materially false and misleading at all relevant times.

To learn more about the Amarin Corporation class action contact jlevi@levikorsinsky.com.

Alta Mesa Resources, Inc. (AMR) f/k/a Silver Run Acquisition Corporation II (AMR)
Class Period:
Purchasers of Silver Run II securities March 24, 2017-February 25, 2019 and investors who held Silver Run II Class A common stock as of January 22, 2018 and were entitled to vote concerning Silver Run II's acquisition of Alta Mesa and Kingfisher Midstream LLC
Lead Plaintiff Deadline: April 1, 2019
Join the action: https://www.zlk.com/pslra-1/alta-mesa-resources-inc-amr-f-k-a-silver-run-acquisition-corporation-ii-loss-form?wire=3

Allegations: Alta Mesa Resources, Inc. (AMR) f/k/a Silver Run Acquisition Corporation II made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) Alta Mesa and Kingfisher did not possess “superior quality” and “[w]orld [c]lass” assets as compared to other operators in the oil and gas industry; (2) Alta Mesa faced significant operational setbacks; (3) several major oil producers had steered assets away from production in the region in which Alta Mesa operates; and (4) Kingfisher and Alta Mesa were not on track to achieve the earnings and production estimates provided in the Proxy and Defendants had no reasonable basis to believe and did not believe that Kingfisher and Alta Mesa would achieve these estimates.

To learn more about the Alta Mesa Resources, Inc. (AMR) f/k/a Silver Run Acquisition Corporation II class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com